Sangamo BioSciences, Inc. announced that the California Institute for Regenerative Medicine has granted the Company a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for beta-thalassemia based on the application of its zinc finger nuclease gene-editing technology in hematopoietic stem cells .
http://www.freshnews.com/news/803203/sangamo-biosciences-receives-6-4-million-strategic-partnership-award-from-california-in
http://www.freshnews.com/news/803203/sangamo-biosciences-receives-6-4-million-strategic-partnership-award-from-california-in
No comments:
Post a Comment